Kornimate/medical-research-clean huggingface dataset:
feasibility study of the my health coach app for adults with fasd

Conditions: Fetal Alcohol Spectrum Disorders

Summary: the purpose of this study is to test a new smartphone "app" for adults with fetal alcohol spectrum disorder (fasd). the app is called my health coach. the goal of the app is to provide adults with useful information and tools to help manage their health and well-being.


Eligibility criteria:
inclusion criteria: * adult 18 years or older * have a fetal alcohol spectrum disorder (fasd) or history of prenatal alcohol exposure * have conversational fluency in english * own an smartphone exclusion criteria: * unable to complete measures or interviews in english * do not have a smartphone * under 18 * do not have an fasd or history or prenatal alcohol exposure
assessment of ability of breath hold for left-sided breast cancer radiation therapy to reduce side effects to heart

Conditions: Breast Cancer

Summary: the purpose of this research study is to demonstrate that deep inspiration breath hold (dibh), the technique used at the university of north carolina (unc) for left-side breast cancer radiation therapy, can reduce side effects to the heart.

the primary objective of this study is to estimate the rate of radiation-associated regional myocardial perfusion defects in patients 6 months after breast/chestwall radiation with dibh for left-sided breast cancer. cardiac perfusion will be assessed using spect cardiac perfusion scans pre- and 6 months post-radiation.

Eligibility criteria:
inclusion criteria: * signed an institutional review board (irb)-approved informed consent document for protocol * age \>= 18 years * histologically confirmed left-sided breast cancer scheduled to undergo curative intent radiation treatment post lumpectomy or mastectomy * stage 0-iii left-sided breast cancer (including dcis) * spect score of 0 at baseline * radiation oncologist agrees target volume coverage will not be compromised via use of the dibh technique along with conformal field shaping exclusion criteria: * active cardiac disease, defined as a history of angina, arrhythmias, myocardial infarction, congestive heart failure, or any other cardiac condition, which in the opinion of the treating physician would make this protocol unreasonably hazardous for the patient * symptomatic pulmonary disease currently requiring regular medication including but not restricted to bronchodilators * concurrent chemotherapy * prior receipt of mediastinal radiation therapy * pregnant or lactating women * inability to understand and follow breathing instructions for the dibh procedure
perinatal depression and adverse childhood experiences: prevention trial

Conditions: Perinatal Depression

Summary: the goal of this clinical trial is to evaluate the impact of rose in individuals with adverse childhood experiences. the main question it aims to answer is, compared to enhanced treatment as usual, does the delivery of rose within a collaborative care model improve depressive symptom trajectories and prevent the development of perinatal depression. participants will be randomized to either enhanced treatment as usual or the rose intervention, delivered by a care manager within a perinatal collaborative care program. they will complete self-reported surveys of their depression symptoms every 4 weeks to inform their symptom trajectories. they will also complete clinical interviews to establish any incident diagnoses of a major depressive episode.

the salience of early life experiences during the transition to parenthood underscores the risk of perinatal depression for those with childhood adversity. mitigation of the adverse effects of childhood adversity via prevention of perinatal depression is an essential component of a reproductive justice-focused public health strategy. whether and how the collaborative care model can be most effectively leveraged to prevent perinatal depression among pregnant people with a history of aces is unknown. to answer these questions, investigators propose a randomized clinical trial of trauma-informed interpersonal therapy modeled after the rose intervention and embedded within a perinatal collaborative care program utilizing a type 2 hybrid effectiveness-implementation design.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * at least one prenatal visit at northwestern medicine * less than 24 weeks gestation * non-anomalous pregnancy * english- or spanish- speaking * ace score ≥ 2 * singleton gestation exclusion criteria: * intent to delivery outside of prentice women's hospital * active major depressive episode * active substance use disorder * participation in a study with a competing intervention or outcome
acute kidney injury in septic critically ill patients : are aminoglycosides really harmful?

Conditions: Acute Kidney Injury; Severe Sepsis

Summary: the purpose of the present study is to determine whether administration of aminoglycosides in septic critically ill patient is a risk factor for acute kidney injury

severe sepsis and septic shock despite recent advances in surviving sepsis campaign remain encumbered by a high mortality rate close to 30%. one cornerstone of the management of these patients remains the early and appropriate antibiotic administration, , which must be also active at the site of infection. aminoglycosides are often administered in combination with beta lactams in this context . according to the progress in pharmacokinetic management achieved over the past decade, their safety and efficiency tended to increase but many uncertainties remain. the purpose of the present study is to determine whether administration of aminoglycosides in septic critically ill patient is a risk factor for acute kidney injury. study design: this is an open retrospective monocentric cohort study including septic critically ill patients from november 2008 to january 2010. to determine the incidence and the specific risk of nephrotoxicity of aminoglycosides, only hospitalized patients without initial acute kidney injury or with rapidly improving kidney function during the three first days will be included.primary outcome will be the occurrence of acute kidney injury assessed with the rifle classification (risk, injury, failure, loss, and end-stage kidney disease) from day 4 to day 15. patients receiving aminoglycosides will be compared with a control group, i.e. not receiving them. we estimated hazard ratios (hr) and 95% confidence intervals (ci) with adjusted and propensity score (ps)-matched cox-proportional hazards models.

Eligibility criteria:
inclusion criteria: * age 18 and older * admission to icu with severe sepsis * hospitalized and without acute kidney injury or with kidney function improved on the third day were included * information provided to the patient or proxy exclusion criteria: * renal replacement therapy before day 3 * patients with renal insufficiency j1 (day 1 creatinine clearance \ 1 + day 3 creatinine clearance \<37.5 ml/mn/1, 73m2 ) without renal replacement therapy still necessary before j3 * prolonged aminoglycosides therapy

Keywords: aminoglycosides acute kidney injury severe sepsis critically ill patient
study of the broad clinical benefit for seroquel xr with flexible dose as an add-on therapy in the treatment of acute bipolar mania patients with partial response to current therapy

Conditions: Acute Bipolar Mania

Summary: the primary objective of this study is to evaluate the broad clinical benefit of dosing seroquel xr with flexible in the treatment of acute bipolar mania patients with partial response to existing therapy. clinical benefit will be assessed with the clinical global impression-clinical benefit (cgi-cb) score, according to a classification based on the principles outlined in the cgi efficacy index. improvement in clinical benefit will be defined as a decrease from baseline in cgi-cb.

a 4-week, multi-centre, open-label, non-comparative, phase iv study of the broad clinical benefit for seroquel xr (quetiapine fumarate extended release) with flexible dose as an add-on therapy in the treatment of acute bipolar mania patients with partial response to current therapy

Eligibility criteria:
inclusion criteria: * documented clinical diagnosis meeting the diagnostic and statistical manual of mental disorders, 4th edition (dsm-iv) criteria (1. bipolar i disorder, manic or mixed type with/without psychotic feature, 2. diagnosis should be confirmed by the mini inte) * currently on lithium/valproate without antipsychotics more than 3 weeks consecutive treatment ymrs total score ≥16 at study entry exclusion criteria: * non-response to antipsychotic treatments for manic symptoms in previous episodes * a patient with diabetes mellitus (dm) fulfilling one of the following criteria (1. unstable dm defined as enrolment glycosylated hemoglobin (hba1c) \>8.5%, 2. admitted to hospital for treatment of dm or dm related illness in past 12 weeks, etc) * an absolute neutrophil count (anc) of 1.5 x 10\^9 per liter

Keywords: acute bipolar mania seroquel xr quetiapine fumarate add-on therapy
ex vivo microbiological assessment of an anti-biofilm catheter in acute dialysis application

Conditions: Hemodialysis

Summary: the clinical study aims at providing data on antimicrobial efficiency and a supposed additional preventive effect on catheter-related infections of a catheter with antibacterial surface coating in comparison to standard catheters without coating.

central venous catheters are increasingly used to provide long-term venous access, e.g. after failure of the primary arteriovenous fistula, and they are the first choice in case of an acute need for extracorporeal therapy. microbial adhesions and biofilm formation have been implicated in serious infections associated with the use of indwelling catheters. in view of the necessity to reduce catheter-related bloodstream infections and of the inadequacy of currently available antimicrobially coated devices, a new antimicrobial catheter surface was developed. the clinical study described below aims at providing further data on antimicrobial efficiency and a supposed additional preventive effect on catheter-related infections.

Eligibility criteria:
inclusion criteria: * central venous catheter placement * need for extracorporeal renal replacement therapy (acute and chronic renal failure) * anticipated duration of dialysis therapy less than or equal to 30 days * age between 18 and 85 years * written informed consent exclusion criteria: * known hepatitis b virus (hbv)/hepatitis c virus (hcv)/human immunodeficiency virus (hiv) infection * known pregnancy

Keywords: dialysis, extracorporeal dialysis, renal extracorporeal dialysis hemodialysis
vitamin d supplementation can improve heart function in idiopathic cardiomyopathy

Conditions: Cardiomyopathy, Dilated

Summary: vitamin d deficiency could be a high risk for cardiovascular diseases. it has been recently reported that vitamin d deficiency is another cause of heart failure and cardiomyopathies. it was found that vitamin d supplementation improved the heart function. the purpose of this study is to evaluate patients with idiopathic cardiomyopathies and determine whether vitamin d supplementation in cases where there is a deficiency, improves heart functioning.


Eligibility criteria:
inclusion criteria: * patients with idiopathic cardiomyopathy exclusion criteria: * post heart surgery * congenital heart disease
signal relief patch in musculoskeletal pain

Conditions: Musculoskeletal Pain

Summary: assess the efficacy of the signal relief patch for the management of general musculoskeletal pain

the signal relief patch is an innovative, non-invasive technology that exists as a thin, flexible patch. the patch contains no drugs, wires, or batteries. nano-capacitors utilized within the signal relief patch were originally developed to replace military antenna systems with no additional power supply. since development, it was incidentally found that these nano-capacitors may help control pain by working with the body's electrical system. although the details of how these nano-capacitors facilitate the alleviation of pain are still under investigation, the possibility of reducing pain through a non-invasive, nonpharmacological method is extremely appealing.

Eligibility criteria:
inclusion criteria: 1. male or female subject aged ≥ 18 years. 2. currently seeking treatment for chronic musculoskeletal pain management. 3. visual analog scale score \> 4 at baseline. 4. willing to refrain from the use of prescription pain medications during study participation. 5. able and willing to provide informed consent. exclusion criteria: - 1. receiving other investigational agents or on another clinical trial. 2. in emergent need for pain management. 3. acute injury requiring rapid intervention or treatment. 4. the subject is using prescription medications (e.g., celecoxib, codeine, oxycodone, prednisone, etc.) for pain management regularly or prn. 5. the subject is currently undergoing or planning to begin physical therapy. 6. the subject is planning to begin a new exercise routine. 7. subject has implantable pain device, pacemaker, defibrillator, or other neuromodulation implantable device 8. known to be pregnant.
safety and effectiveness of low-flow ecmo driving by cvvh machine in severe ncp

Conditions: COVID-19; ECMO

Summary: assess the safety and effectiveness of using low-flow extracorporeal membrane oxygenation(co2 removal) driving by cvvh machine in the severe ncp patients


Eligibility criteria:
inclusion criteria: * 1. ncp with severe acute respiratory distress syndrome with ratio of partial pressure of arterial oxygen over fraction of inspired oxygen (pao2:fio2)\ 10cmh2o * 2. driving pressure\> 20cmh2o * 3. rr\>30bpm * 4.paco2\>55cmh2o and/or ph\>7.3 exclusion criteria: * 1. poor venous vascular condition and unavaible for central venous catheter placement
single dose intravenous iron isomaltoside in combination with oral iron vs oral iron monotherapy in patients with anemia after postpartum haemorrhage

Conditions: Post Partum Hemorrhage; Anemia

Summary: the investigator's study is going to compare effectiveness of single dose intravenous iron in combination with oral iron versus oral iron monotherapy in correcting haemoglobin deficit, replenishing iron stores and improving clinical symptoms in women with post-partum anaemia after postpartum hemorrhage without increasing the rate of adverse outcomes.


Eligibility criteria:
inclusion criteria: * women who underwent spontaneous vaginal delivery with post partum hemorrhage (pph) ≥ 500ml or women who underwent lower segment caesarean section with pph ≥ 1000 ml * post pph haemoglobin level ≤ 10.0 g/dl measured within 48hrs after delivery and stabilisation \& resuscitation. * ≥ 18 years of age * proficient in malaysian language or english language * willingness to consent for blood taking and attending follow-up at 2 weeks and 6 weeks exclusion criteria: * refused consent to participate in trial * history of hemolytic anemia, thalassemia , and sickle cell anemia * women with signs of sepsis (clinical or laboratory evidence-intrapartum fever \>38.5 degrees with abnormal vital signs, positive blood culture) * clinical or laboratory evidence of hepatic or renal, cardiovascular and hemolytic abnormalities * history of active severe acid peptic disorder, esophagitis or hiatus hernia and malabsorption syndrome. * severe symptoms of anemia including dyspnoea at rest, angina pectoris, syncope or transient ischemic attacks. * history of severe asthma, eczema or other atopic allergy * known allergy to iron * patients with known immune or inflammatory conditions (e.g. systemic lupus erythematosus, rheumatoid arthritis).
cancer survivor cardiomyopathy detection

Conditions: Cardiovascular Diseases; Cancer

Summary: the purpose of this study is to improve the cardiovascular care of adult cancer survivors. the goal is to obtain the data necessary to plan and develop a nation-wide network of a screening program that can help provide cost-effective and long-term monitoring.

the primary objective of this study is to define the diagnostic performance and optimal cutoffs of ai-ecg and nt-pro-bnp for the detection of left ventricular dysfunction \[lvd, defined as a left ventricular ejection fraction (lvef) \<50%\] in cancer patients at 1 year after completion of anthracycline-based chemotherapy.

Eligibility criteria:
inclusion criteria: * ≥18 years of age prior to enrollment and anthracycline start date * diagnosis of breast cancer, lymphoma, or sarcoma with either planned or at 1 year after completion of anthracycline therapy, including patients from 6-12 months and greater than 1 year post-anthracycline exposure. * patients with a history of persistent atrial fibrillation (afib) that are not in afib remission. include if the most recent ecg does not show afib. atrial flutter treated the same exclusion criteria: * lvef \<50% or prior confirmed history of cardiomyopathy, heart failure, left bundle branch block, or paced rhythm * patients with a history of persistent atrial fibrillation (afib) that are not in afib remission. include if the most recent ecg does not show afib. atrial flutter treated the same. * individuals with pacemakers, defibrillators, or other implanted electronic devices * inability/unwillingness of individual to give written informed consent
effects of vitamin b3 in patients with ataxia telangiectasia

Conditions: Ataxia Telangiectasia; ATM Gene Mutation

Summary: this clinical trial investigates the effects of nicotinamide riboside (vitamin b3) on the disease course of patients with ataxia telangiectasia. patients will be treated during four consecutive months with nicotinamide riboside (25mg/kg/day), followed by a washout period of two months. main study parameters/endpoints: ataxia, dysarthria, quality of life, laboratory parameters.

rationale: ataxia telangiectasia (a-t) is an autosomal recessively inherited neurodegenerative disorder, with a high cancer risk, that also affects the immune and respiratory system. therapy for a-t is restricted to symptomatic treatment including rehabilitation care, combined with infection prevention and treatment, and screening for pulmonary dysfunction and malignancies. a-t is caused by mutations in the atm gene. the atm protein plays a pivotal role in more than 100 different biochemical processes, among which cellular energy metabolism, cell signaling, and dna repair. nicotinamide adenine dinucleotide (nad+) is an essential molecule in many of these processes and studies have shown that nad+ deficiency plays a role in disease mechanisms underlying dna repair disorders such as a-t. nad+ is available in food, but can also be synthesized in the body from its precursors nicotinamide, nicotinic acid, and nicotinamide riboside (nr), as a group called "vitamin b3". treatment of experimental a-t animal models with nr showed beneficial effects. the aim of this study is to investigate whether treatment with nr during a period of six months may have positive effects on the disease course of patients with a-t. objective: to investigate the effects of nr on the disease course of patients with ataxia telangiectasia. study design: single center, interventional, explorative, open-label proof of concept study. study population: patients with a-t (age \>2 years). intervention (if applicable): patients will be treated with nicotinamide riboside (25mg/kg/day), during four consecutive months, followed by a washout period of two months. main study parameters/endpoints: ataxia, dysarthria, quality of life, laboratory parameters.

Eligibility criteria:
inclusion criteria: * a-t patients who visit our outpatient clinic. * genetically confirmed diagnosis of a-t by the identification of pathogenic mutations of the atm gene. * age ≥ 2 years or older and bodyweight ≥ 12 kg. * informed consent. exclusion criteria: * additional medical condition or illness that impair the patient's ability to participate in the study (e.g. actual treatment of a malignancy, active infection, poorly controlled diabetes mellitus, hypertension, organ failure, clinically significant hematological or biochemical abnormalities different from the usual abnormalities in a-t) * elevated serum transaminases (\> 2 times upper limit of normal) * participation in another interventional study at start of the study or during the study * pregnancy. * breast feeding.

Keywords: ataxia telangiectasia atm gene mutation atm protein nicotinamide riboside
pathophysiology of inborn immunodeficiencies

Conditions: Primary Immune Deficiency Disorder

Summary: the pathophysiology of primary immunodeficiencies (pid), which encompass a broad range of different diseases with susceptibility to infection and/or a deregulated inflammatory response, is poorly understood. available treatments are often not specific for a distinct target and might be associated with side effects. to elucidate pathophysiology of different pids, stool, urine, blood, tissue biopsies and/or bone marrow will be collected and analysed for anti-microbial activity and inflammatory response. in a second step, targeted treatment for different pids might be developed preclinically and ex vivo according to underlying pathophysiology.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of an inborn error of immunity (primary immunodeficiency, pid) * clinically healthy (non-age matched) volunteer exclusion criteria: * exclusion of an inborn error of immunity * secondary immunodeficiency * refusal to enter the study
nordic pole walking for individuals with cancer

Conditions: Cancer; Neoplasms

Summary: individuals diagnosed with cancer tend to be inactive and have symptom burdens that impact quality of life. a community-based nordic pole walking (npw) program may help. the primary objective of this study was to see if it was feasible to do to a larger trial. the secondary objective was to determine the effects of npw on physical function and health-related quality of life (hrqol). npw or no npw was randomly assigned to adults with non-small cell lung, prostate, colorectal, and endometrial. eight people were enrolled in the study with 4 in the npw group (1 dropped out) and 4 in the no npw group.

individuals diagnosed with cancer tend to be inactive and have symptom burdens that impact quality of life. an individualized, community-based nordic pole walking (npw) program may help. the primary objective of this study was to assess feasibility using the thabane framework of a randomized controlled trial (rct). the secondary objective was to determine the effects of npw on physical function (six-minute walk test, 30-second \[30-s\] chair stand test, unsupported upper limb exercise test, handgrip strength, physical activity \[pa\]), and health-related quality of life (hrqol, 36-item short form health \[sf-36\]). the study design was an eight-week multi-centred block randomized controlled feasibility study (no blinding) comparing a npw program (versus usual daily routine) for adults with non-small cell lung, prostate, colorectal, and endometrial cancer, from hospitals and cancer support groups.

Eligibility criteria:
inclusion criteria: * a primary diagnosis (including reoccurrence) of histologically confirmed stage i-iv nsclc, prostate, colorectal, or endometrial cancer (with any concurrent cancer treatment) * a cancer diagnosis or treatment within the last three years * ≥ 55 years old * approval by the primary treating physician * ability to communicate in english. exclusion criteria: • engaged in npw within the last six-months

Keywords: nordic pole walking exercise rehabilitation